Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Brigitte C. Widemann(National Cancer Institute), Frank M. Balis(National Institutes of Health), Alyssa Reddy, Seth M. Steinberg(National Institutes of Health), Staci Martin(National Institutes of Health), Elizabeth Fox(Children's National), A. Kim(Children's National), Eva Dombi(National Institutes of Health), J. J. Wright(National Institutes of Health), Jeffrey Solomon, Mark W. Kieran(Children Cancer Hospital), Pamela L. Wolters(National Cancer Center), Andrea Gillespie(National Institutes of Health), Stewart Goldman(St Nicholas Hospital), John P. Perentesis(University of Southern California), Jean B. Belasco(California University of Pennsylvania), Wanda L. Salzer(Maine Medical Center), N Patronas(United States Army Medical Research and Development Command), Bruce R. Korf(University of Alabama at Birmingham)
Cited by 114
Related Papers
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma
|Nature Genetics|2014|464